Skip to content
Screener

Oric Pharmaceuticals, Inc. ORIC Q4 2025 Annual earnings

Reported February 23, 2026 · Before market open

EPS-$0.30Beat by $0.04
EPS estimate-$0.34

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.40

Financials

Q4 2025

Income statement

See full
Operating income-$34.6M+12.7%
Net income-$30.5M+16.0%
EPS (diluted)-$0.27+47.1%

Balance sheet

See full
Cash & equivalents$45.7M-23.1%
Total debt$7.4M-20.5%
Total equity$384.4M+58.1%
Total assets$408.9M+49.2%

Cash flow

See full
Operating cash flow-$22.5M+19.9%
CapEx$227.0K+3.7%
Free cash flow-$22.7M+19.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$796.64M+39.9%
Enterprise value$758.42M+46.0%

Returns & leverage

See full
Return on equity-41.3%-8.1pp
Debt / equity0×0.0×
Current ratio14.1×+3.6×

FAQ

When did Oric Pharmaceuticals, Inc. report Q4 2025 earnings?
Oric Pharmaceuticals, Inc. (ORIC) reported Q4 2025 earnings on February 23, 2026 before market open.
What were Oric Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Oric Pharmaceuticals, Inc. reported eps of $-0.30 for Q4 2025.
Did Oric Pharmaceuticals, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.34 by $0.04.
How did Oric Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 41.2% from $-0.51.
Where can I find Oric Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-063974) and the 10-K periodic report (0001193125-26-064005) directly on SEC EDGAR. The filing index links above go to sec.gov.